Peptide-Oligonucleotide Conjugates (POCs) Synthesis

Introduction Therapeutic oligonucleotide manufacturing depends on Phosphoramidite Solid-Phase Synthesis to assemble custom single-stranded and double-stranded nucleic acid sequences at scales […]

Introduction: Peptide-Oligonucleotide Conjugation Yield Optimization is the systematic improvement of the reaction and recovery processes used to make a peptide-linked

Introduction: Peptide-oligonucleotide conjugates for oncology are engineered molecules in which a peptide is chemically linked to an oligonucleotide designed to

Introduction: The ICH guidelines for peptide-oligonucleotide conjugates give developers a scientifically justified framework, even though no single ICH guideline is

Introduction Developing robust Reference Standards and Analytical Method Validation strategies for peptide-oligonucleotide conjugates (POCs) is critical for establishing biopharmaceutical identity,

Introduction: GMP Manufacturing of Peptide-Oligonucleotide Conjugates requires a manufacturing strategy that accounts for the distinct chemical and analytical characteristics of

Introduction The GMP Manufacturing of Peptide-Oligonucleotide Conjugates requires a Contract Research Organization (CRO) or Contract Development and Manufacturing Organization (CDMO)

Introduction Selecting between a Phosphorothioate vs Phosphodiester Backbone for peptide-oligonucleotide conjugate (POC) design involves carefully balancing metabolic stability and bio-distribution

Introduction Covalently attaching functional peptide vectors to synthetic nucleic acids can substantially modify the pharmacokinetics and biodistribution of oligonucleotide therapeutics

Introduction: Peptide-oligonucleotide conjugate (POC) developers face a question that shapes every downstream decision — from IND strategy to exclusivity planning: